Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
08. März 2024 11:00 ET
|
Zealand Pharma
Company announcement – No. 13 / 2024 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons ...
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
05. März 2024 16:05 ET
|
Zealand Pharma
Company announcement – No. 12 / 2024 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons ...
Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants
05. März 2024 16:00 ET
|
Zealand Pharma
Company announcement – No. 11 / 2024 Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants Copenhagen, Denmark, March 5, 2024 – Zealand Pharma A/S (“Zealand”)...
Zealand Pharma to Participate in TD Cowen’s 44th Annual Health Care Conference
01. März 2024 11:00 ET
|
Zealand Pharma
Press release – No. 3 / 2023 Zealand Pharma to Participate in TD Cowen’s 44th Annual Health Care Conference Copenhagen, Denmark, March 1, 2024 – Zealand Pharma A/S (Nasdaq Copenhagen:...
Zealand Pharma convenes its Annual General Meeting 2024
27. Februar 2024 01:05 ET
|
Zealand Pharma
Company Announcement – No. 10 / 2024 Zealand Pharma convenes its Annual General Meeting 2024 Notice to convene the Annual General Meeting of Zealand Pharma A/S (CVR no. 20 04 50 78) (the...
Zealand Pharma Announces Financial Results for the Full Year 2023
27. Februar 2024 01:00 ET
|
Zealand Pharma
Company announcement - No. 9 / 2024 Zealand Pharma Announces Financial Results for the Full Year 2023 Significant progress delivered across our obesity and rare disease assets while building a...
Zealand Pharma announces Boehringer Ingelheim survodutide Phase 2 trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis
26. Februar 2024 02:06 ET
|
Zealand Pharma
Company announcement - No. 8 / 2024 Zealand Pharma announces Boehringer Ingelheim survodutide Phase 2 trial shows 83% of adults treated achieved groundbreaking results in liver disease due to...
Zealand Pharma conference call on February 27 at 2pm CET (8am ET) to present full year 2023 financial results
20. Februar 2024 02:00 ET
|
Zealand Pharma
Press Release – No. 2 / 2024 Zealand Pharma conference call on February 27 at 2pm CET (8am ET) to present full year 2023 financial results Copenhagen, Denmark, February 20, 2024 – a Zealand...
Total number of shares and voting rights in Zealand Pharma at January 31, 2024
31. Januar 2024 11:00 ET
|
Zealand Pharma
Company announcement – No. 7 / 2024 Total number of shares and voting rights in Zealand Pharma at January 31, 2024 Copenhagen, Denmark, January 31, 2024 – Zealand Pharma A/S (“Zealand”)...
Zealand Pharma major shareholder announcement: Van Herk Investments
26. Januar 2024 12:00 ET
|
Zealand Pharma
Company announcement – No. 6 / 2024 Zealand Pharma major shareholder announcement: Van Herk Investments Copenhagen, Denmark, 26 January 2024 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no....